Literature DB >> 27134134

Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.

Steffen Halbgebauer1, Patrick Öckl1, Katharina Wirth1, Petra Steinacker1, Markus Otto1.   

Abstract

Despite extensive research, to date, no validated biomarkers for PD have been found. This review seeks to summarize studies approaching the detection of biomarker candidates for PD and introduce promising ones in more detail, with special attention to synaptic proteins. To this end, we performed a PubMed search and included studies using proteomic tools (2-dimensional difference in gel electrophoresis and/or mass spectrometry) for the comparison of samples from PD and control patients. We found 27 studies reporting more than 500 differentially expressed proteins in which a total of 28 were detected in 2 and 17 in 3 or more independent studies, including posttranslationally modified proteins. In addition, of these 500 proteins, 25 were found to be brain specific, and 14 were enriched in synapses. Special attention was given to the applicability of the biomarker regarding sampling procedures, that is, using CSF/serum material for diagnosis. Furthermore, presynaptic proteins involved in vesicle membrane fusion seem to be interesting candidates for future analyses. Nonetheless, even though such promising biomarker candidates for PD exist, validation of these biomarkers in large-scale clinical studies is necessary to evaluate the diagnostic potential.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cerebrospinal fluid; protein biomarker; proteomics; synapse

Mesh:

Substances:

Year:  2016        PMID: 27134134     DOI: 10.1002/mds.26635

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.

Authors:  Li Yang; Tessandra Stewart; Min Shi; Gwenael Pottiez; Romel Dator; Rui Wu; Patrick Aro; Robert J Schuster; Carmen Ginghina; Catherine Pan; Yuqian Gao; Weijun Qian; Cyrus P Zabetian; Shu-Ching Hu; Joseph F Quinn; Jing Zhang
Journal:  Proteomics Clin Appl       Date:  2017-04-19       Impact factor: 3.494

Review 2.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

Review 3.  Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.

Authors:  Xin Li; Xiaoying Fan; Hongtian Yang; Yufeng Liu
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

4.  Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.

Authors:  Patrick Oeckl; Fabian Metzger; Magdalena Nagl; Christine A F von Arnim; Steffen Halbgebauer; Petra Steinacker; Albert C Ludolph; Markus Otto
Journal:  Mol Cell Proteomics       Date:  2016-08-09       Impact factor: 5.911

Review 5.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

6.  Alpha-synuclein is present in dental calculus but not altered in Parkinson's disease patients in comparison to controls.

Authors:  Sabrina Schmid; Eva Goldberg-Bockhorn; Silke Schwarz; Nicole Rotter; Jan Kassubek; Kelly Del Tredici; Elmar Pinkhardt; Markus Otto; Albert C Ludolph; Patrick Oeckl
Journal:  J Neurol       Date:  2018-03-29       Impact factor: 4.849

7.  Decreased serum proNGF concentration in patients with Parkinson's disease.

Authors:  Xiao-Min Xu; Mei-Xue Dong; Xia Feng; Yang Liu; Jun-Xi Pan; Shi-Yu Jia; Du Cao; You-Dong Wei
Journal:  Neurol Sci       Date:  2017-10-19       Impact factor: 3.307

Review 8.  Mediterranean Diet in Preventing Neurodegenerative Diseases.

Authors:  Hannah Gardener; Michelle R Caunca
Journal:  Curr Nutr Rep       Date:  2018-03

9.  Skeletal muscle transcriptional networks linked to type I myofiber grouping in Parkinson's disease.

Authors:  Kaleen M Lavin; Stuart C Sealfon; Merry-Lynn N McDonald; Brandon M Roberts; Katarzyna Wilk; Venugopalan D Nair; Yongchao Ge; Preeti Lakshman Kumar; Samuel T Windham; Marcas M Bamman
Journal:  J Appl Physiol (1985)       Date:  2019-12-12

10.  Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach.

Authors:  Erika Bereczki; Rui M Branca; Paul T Francis; Joana B Pereira; Jean-Ha Baek; Tibor Hortobágyi; Bengt Winblad; Clive Ballard; Janne Lehtiö; Dag Aarsland
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.